Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

UCB, INC.

Filed by THE NICKLES GROUP, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 16, 2025
Income
$60,000.00
Expenses
Not reported
Client
UCB, INC.
Filing UUID
7edbad7a-644f-407f-9af9-a0006a07ebc2
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to access to home infusion, including H.R. 993, Joe Fiandra Access to Home infusion Act of 2025. H.R. 946/S.1862, ORPHAN Cures Act. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Literal federal measure citations: H.R. 993, H.R. 946, S.1862, H.R. 1

TAX · Taxation/Internal Revenue Code

Issues related to the Orphan Drug Tax Credit. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes.

Literal federal measure citations: H.R. 1

HCR · Health Issues

Issues related to medication step therapy. S.864, HELP Copays Act, as it relates to out-of-pocket costs for prescription drugs. Issues related to pharmacy benefit management reforms.

Literal federal measure citations: S.864

TRD · Trade (domestic/foreign)

Issues related to tariffs.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.